Genetically Modified Cells for Prostate Cancer Immune Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, such as chemotherapy and radiation therapy, have limitations in efficacy and toxicity, and there is a need for improved methods to enhance the immune response against prostate cancer.
Innovation Solution
Genetically modified cells expressing cytokines and prostate tumor-associated antigens, such as HLA-A24, FLJ14668, Cardiolipin, NNAT, SELS, HIGD2A, SSR3, and NRP2, are administered to induce or increase a humoral immune response, potentially leading to the treatment or prophylaxis of prostate cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard medical treatments (chemotherapy, radiation therapy) are used to treat prostate cancer, then tumor size is reduced, but toxicity increases and efficacy is limited
Solution Approach 1:
The patent uses genetically modified cells as intermediaries to deliver cytokines and tumor-associated antigens to the immune system. These modified cells act as mediators between the treatment and the cancer, inducing an immune response without the direct toxicity of chemotherapy or radiation. The cytokine-expressing cells stimulate immune cells to attack tumor cells, providing a less toxic alternative that maintains efficacy through immune-mediated tumor destruction.
2Reliability
If genetically modified cells expressing cytokines and tumor-associated antigens are administered, then immune response against prostate cancer is enhanced, but device complexity increases
Solution Approach 1:
The genetically modified cells perform multiple functions simultaneously: they express cytokines to stimulate immune activation, present tumor-associated antigens to guide immune specificity, and serve as vectors for delivering therapeutic genes. This multi-functionality consolidates what would otherwise require separate treatment components into a single universal therapeutic agent, reducing overall system complexity while maintaining enhanced immune response efficacy.
3Adaptability or versatility
If multiple tumor-associated antigens are targeted to induce comprehensive immune response, then coverage of prostate cancer variants increases, but manufacturing complexity increases
Solution Approach 1:
The patent combines multiple tumor-associated antigens (such as PSA, PSCA, and other prostate cancer-specific antigens) into a single genetically modified cell line. This merging approach allows the cell to simultaneously present multiple antigens to the immune system, providing comprehensive coverage of different prostate cancer variants. The manufacturing process is simplified compared to producing separate vaccines for each antigen, as all antigens are expressed within the same cellular platform.
Data Source
AI summary
The present invention relates to prostate cancer markers, compositions comprising such markers, and methods of using such markers to induce or increase an immune response against prostate cancer. An immune response against the markers correlates with an immune response, in particular a humoral immune response, against prostate cancer cells which immune response is preferably associated with prophylaxis of prostate cancer, treatment of prostate cancer, and/or amelioration of at least one symptom associated with prostate cancer.